CR20160348A - Compuestos - Google Patents

Compuestos

Info

Publication number
CR20160348A
CR20160348A CR20160348A CR20160348A CR20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A CR 20160348 A CR20160348 A CR 20160348A
Authority
CR
Costa Rica
Prior art keywords
disease
activity
compounds
lrrk2 kinases
lrrk2
Prior art date
Application number
CR20160348A
Other languages
English (en)
Inventor
Xiao; Ding
Colin Michael Edge
Yingxia; Sang
Baowei; Zhao
Qian; Liu
Luigi Piero Stasi
Zehong; Wan
Original Assignee
Glaxosmithline Intellectual Property Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithline Intellectual Property Dev Ltd filed Critical Glaxosmithline Intellectual Property Dev Ltd
Publication of CR20160348A publication Critical patent/CR20160348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que inhiben la actividad de las cinasas LRRK2, procesos para su preparación, composiciones que las contienen y su uso en el tratamiento o la prevención de enfermedades caracterizadas por la actividad de las cinasas LRRK2, por ejemplo, la enfermedad de Parkinson, la enfermedad de Alzheimer y la esclerosis lateral amiotrófica (ELA).
CR20160348A 2014-01-29 2015-01-28 Compuestos CR20160348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29
PCT/CN2015/000055 WO2015113452A1 (en) 2014-01-29 2015-01-28 Compounds

Publications (1)

Publication Number Publication Date
CR20160348A true CR20160348A (es) 2017-04-28

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160348A CR20160348A (es) 2014-01-29 2015-01-28 Compuestos

Country Status (20)

Country Link
US (2) US10087186B2 (es)
EP (1) EP3099695B1 (es)
JP (1) JP6422986B2 (es)
KR (1) KR20160106622A (es)
CN (1) CN105940004B (es)
AU (2) AU2015210593A1 (es)
CA (1) CA2937431A1 (es)
CL (1) CL2016001895A1 (es)
CR (1) CR20160348A (es)
DO (2) DOP2016000195A (es)
EA (1) EA029774B1 (es)
ES (1) ES2802174T3 (es)
IL (1) IL246579B (es)
MA (1) MA39219B1 (es)
MX (1) MX367370B (es)
PE (1) PE20161443A1 (es)
PH (1) PH12016501307B1 (es)
SG (1) SG11201605342UA (es)
UA (1) UA118369C2 (es)
WO (1) WO2015113452A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
SG11201605342UA (en) 2014-01-29 2016-08-30 Glaxosmithkline Ip Dev Ltd Compounds
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CN114315819A (zh) 2016-06-16 2022-04-12 戴纳立制药公司 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑
EP3573956A4 (en) 2017-01-25 2020-08-12 GlaxoSmithKline Intellectual Property Management Limited LINKS
EP3587422A4 (en) * 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE
FI3604304T3 (fi) 2017-03-23 2022-12-15 Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi
CA3083583A1 (en) * 2017-12-05 2019-06-13 Oscotec Inc. Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
AU2019350717A1 (en) * 2018-09-25 2021-05-27 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
KR20230091150A (ko) * 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
TW202330549A (zh) 2021-10-27 2023-08-01 丹麥商Ｈ 朗德貝克公司 Lrrk2抑制劑
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商Ｈ 朗德貝克公司 富白胺酸重複激酶2（lrrk2）抑制劑

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070542A1 (en) 2003-09-03 2005-03-31 Hodgetts Kevin J. 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005299089B2 (en) 2004-10-21 2011-08-18 Eberhard Karls Universitaet Tuebingen KASPP (LRKK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
US20080004295A1 (en) 2005-10-13 2008-01-03 Gore Paul M Novel compounds
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
EP2483254B1 (en) * 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP5986094B2 (ja) 2010-11-10 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
TWI606049B (zh) 2011-04-21 2017-11-21 原真股份有限公司 新穎激酶抑制劑
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
KR101996699B1 (ko) * 2011-11-30 2019-07-04 제넨테크, 인크. Lrrk2에 대해 양전자 방사 단층촬영(pet) 이미징을 위한 불소-18 및 탄소-11 표지된 방사선 리간드
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
MX363118B (es) 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
EP2844658B1 (en) 2012-05-03 2019-03-20 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
JP6189948B2 (ja) * 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
SG11201605342UA (en) 2014-01-29 2016-08-30 Glaxosmithkline Ip Dev Ltd Compounds

Also Published As

Publication number Publication date
AU2018200277B2 (en) 2019-09-26
UA118369C2 (uk) 2019-01-10
MA39219A1 (fr) 2017-09-29
EP3099695B1 (en) 2020-04-08
KR20160106622A (ko) 2016-09-12
US20170015668A1 (en) 2017-01-19
IL246579A0 (en) 2016-08-31
PH12016501307A1 (en) 2016-08-15
DOP2019000010A (es) 2019-03-15
PE20161443A1 (es) 2017-01-06
CN105940004A (zh) 2016-09-14
US10087186B2 (en) 2018-10-02
EP3099695A4 (en) 2017-07-12
CL2016001895A1 (es) 2016-12-09
DOP2016000195A (es) 2016-10-31
JP6422986B2 (ja) 2018-11-14
EA029774B1 (ru) 2018-05-31
US10618901B2 (en) 2020-04-14
CN105940004B (zh) 2018-02-02
AU2018200277A1 (en) 2018-02-01
EA201691514A1 (ru) 2016-12-30
MX2016009893A (es) 2016-10-31
AU2015210593A1 (en) 2016-07-07
JP2017504631A (ja) 2017-02-09
EP3099695A1 (en) 2016-12-07
MA39219B1 (fr) 2018-11-30
SG11201605342UA (en) 2016-08-30
WO2015113452A1 (en) 2015-08-06
PH12016501307B1 (en) 2016-08-15
ES2802174T3 (es) 2021-01-15
MX367370B (es) 2019-08-16
US20180354956A1 (en) 2018-12-13
CA2937431A1 (en) 2015-08-06
IL246579B (en) 2019-05-30

Similar Documents

Publication Publication Date Title
DOP2016000195A (es) Compuestos
UY37808A (es) Nuevos compuestos que inhiben la actividad quinasa de la lrrk2
BR112018001303A2 (pt) ?compostos?
CO2017011851A2 (es) Compuestos novedosos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CO2017004465A2 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2021003905A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
BR112017008045A2 (pt) compostos como inibidores de nik
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
SV2016005306A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
BR112017025263A2 (pt) método para o tratamento de doença neurológica
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7